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The mammalian tumor necrosis factor (TNF) cytokine is a central mediator of inflamma-
tory events. Recent studies revealed a number of complex and sophisticated interactions
between the TNF pathway and the enzymatic activities encoded by ubiquitin ligases and
deubiquitylation enzymes. However, very little is known about the identity of the ubiquitin
pathway members that control the extent of ubiquitylation in TNF responses. To address
this deficit, we conducted an unbiased, high-content screen of the human ubiquitin path-
way for gene products that control defining features of the cellular response to TNF. In
particular, we sought to identify ubiquitin modifying enzymes that alter the ability ofTNF to
regulate the nuclear accumulation of nuclear factor kappa B. In this screen, we identified
and validated several novel regulators of theTNF pathway.We believe these regulators con-
stitute potential targets for pharmacological interventions that manipulate TNF-dependent
inflammation.
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INTRODUCTION
The mammalian tumor necrosis factor (TNF) cytokine directs
immunological responses to pathogenic microbes and is a cen-
tral feature of numerous inflammatory illnesses (1). Physiological
responses to TNF involve a complex series of events that include
the activation, differentiation, mobilization, and extravasation of
leukocytes, or the induction of cell death. Inflammation prevents
the spread of microbial invaders, promotes the repair of damaged
host tissues, and drives sophisticated secondary immune responses
in mammals (2). Chronic inflammation drives persistent cycles
of tissue destruction and repair that are implicated in pathologi-
cal conditions such as rheumatoid arthritis, inflammatory bowel
disease, and multiple sclerosis (3, 4). Persistent inflammation
also establishes a micro-environment that favors the develop-
ment and growth of cancerous lesions through the promotion
of angiogenesis, proliferation, tissue invasion, and metastasis (5).
Given the critical links between cytokine signaling, immunity,
and disease, there is considerable interest in the molecular path-
ways that translate detection of a cytokine into induction of a host
response. Myeloid cells such as dendritic cells, macrophages, and
mast cells release soluble TNF homotrimers in response to the
molecular signatures of pathogenic invasion (6). Trimeric TNF
induces dissociation of the suppressor of death domain (SODD)
protein from homotrimers of the TNF receptor (TNFR) (7). The
release of SODD exposes TNFR death domains that nucleate a
complex arrangement of adaptor proteins, kinases, and ubiqui-
tin ligases. Current models suggest that homotypic interactions
between the death domains of the TNFR and the TNF receptor
associated death domain (TRADD) (8) lead to the formation of
a membrane-associated signaling complex, commonly referred to
as complex I (9). Complex I contains TNFR, TRADD, the adaptor
molecule receptor-interacting serine/threonine–protein kinase-1
[RIPK1 (10)], the ubiquitin ligase TNF receptor associated fac-
tor 2 [TRAF2 (11)], and the ubiquitin ligase cellular inhibitor of
apoptosis proteins 1 and 2 [c-IAP1/2 (12)].
The ubiquitin ligase activities of cIAPs are essential for the
recruitment of pro-inflammatory kinases to complex I. Activa-
tion of ubiquitin involves the serial transfer of ubiquitin mole-
cules from E1 ligases to E2 ligases to terminal E3 ligases (13).
E3 ligases transfer ubiquitin to substrate proteins in a number
of different lysine-linked configurations. K48-linked ubiquitin
chains target substrates for proteasomal destruction, while K63-
linked chains modify the localization or actions of a substrate.
In the TNF pathway, cIAPs drive the K63-conjugation of ubiq-
uitin to a number of substrate proteins within complex I (14).
Ubiquitin binding motifs on the TGF-beta activated kinase bind-
ing protein 2 (TAB2) integrate the transforming growth factor
beta-activated kinase-1 (TAK1) kinase into complex I (15), and
ubiquitin binding motifs on NF-κB essential modifier (NEMO)
recruit the I-κB kinase (IKK) complex (16–18). TAB2–TAK1
transduces pro-inflammatory signals by the activation of c-Jun
N-terminal kinase (JNK) and IKK phosphorylates inhibitor of
kappa B (I-κB) proteins. In resting cells, I-κB binds and retains
nuclear factor kappa B (NF-κB) transcription factors in the
cytosol. Phosphorylation of I-κB results in the attachment of
K48-linked ubiquitin proteins to I-κB by the SKP1-CUL-F-box-
beta-transducin repeat containing (SCF–bTrCP) E3 ligase, leading
to the proteasomal destruction of I-κB, the nuclear translocation
of NF-κB, and the transcriptional induction of pro-inflammatory
genes (19).
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Recent studies established that K63-linked substrates in com-
plex I recruit a novel ubiquitin ligase, the linear ubiquitin chain
assembly complex (LUBAC) (20). LUBAC catalyzes the forma-
tion of a linear chain of ubiquitin proteins in which the C-
terminal residue of one ubiquitin protein is covalently linked to
the alpha-amino group of a second ubiquitin protein through
a peptide bond. Biochemical studies demonstrated that LUBAC
ubiquitylates RIPK1 and NEMO, and LUBAC contributes to the
transduction of signals from complex I to NF-κB transcription
factors.
Ubiquitin modification is also a central feature of the termi-
nation of TNF signals. Prolonged signals through the TNFR lead
to the formation of a pro-apoptotic complex II that accompa-
nies TNFR endocytosis (9). Complex II retains a core of TNFR,
RIPK1, TRADD, and TRAF2, and recruits the pro-apoptotic adap-
tor protein Fas-associated death domain (FADD) and the initiator
caspase, caspase-8. Caspase-8 is a proximal element in the induc-
tion of programed cell death by extrinsic cues (21). TNF signals
rarely lead to the activation of caspase-8, as NF-κB induces the
transcription of a number of proteins that effectively limit the
extent of TNF signaling. For example, NF-κB induces the expres-
sion of the NF-κB inhibitor I-κB, the caspase-8 inhibitor FLIPL
(22), and the ubiquitin-editing enzyme A20 (23). A20 encodes
ubiquitin ligase and deubiquitylation domains that act in a coor-
dinated manner to disassemble complex I and target RIPK1 for
destruction (24).
Given the involvement of ubiquitylation in TNF signaling and
the extensive involvement of TNF in health and disease, there
is a burgeoning interest in deciphering the precise relationship
between the TNF and ubiquitin pathways. We present a simple,
high-content assay that reliably quantifies nuclear translocation
of NF-κB in cells treated with recombinant TNF. In an unbi-
ased siRNA screen of the entire complement of deubiquitylation
enzymes, and E1, E2, and E3 ubiquitin ligases in the human
genome, we identified a number of enzymes that modify the
extent to which TNF directs the nuclear accumulation of NF-
κB. We believe that these enzymes represent potential targets
for pharmacological manipulations that control inflammatory
condition.
MATERIALS AND METHODS
CELL CULTURE
HeLa cells were cultured in Dulbecco’s modified Eagle Medium
with 4.5 g/l d-glucose and l-glutamine (Gibco) and A549 cells
were cultured in Dulbecco’s modified Eagle Medium/F12 (1:1)
with l-glutamine and 15 mM HEPES (Gibco). Both were supple-
mented with 10% fetal bovine serum (Gibco) and 50 U/ml peni-
cillin and 50µg/ml streptomycin (Gibco). Cells were maintained
in an incubator at 37°C with 5% CO2.
HIGH-CONTENT IMAGING
All liquid handling steps were performed with a Janus Worksta-
tion (Perkin Elmer) unless stated otherwise. Plates were treated
with TNF for 30 or 120 min. Medium was aspirated from the
cells and 50µl DMEM culture medium (+FBS/−antibiotics) con-
taining 10 ng/ml TNF-alpha was added to each well. Plates were
incubated at 37°C for the appropriate amount of time. Medium
containing TNF was aspirated and cells were washed with 150µl
PBS per well. Plates were rocked manually 10–15 times then placed
on a shaker. PBS was manually dumped from plates and 150µl
3.7% formaldehyde in PBS was added to each well using a multi-
channel pipette. Plates were rocked manually 10–15 times and
incubated at room temperature for at least 15 min without shak-
ing. Formaldehyde was manually dumped from the plates. Plates
were washed with 150µl 1×PBS/0.1% Triton for 6 min while shak-
ing at room temperature, four times. The wash solution was added
with the Janus Workstation and dumped manually. Fifty micro-
liters of 5% NGS in 1×PBS/0.1% Tween (blocking reagent) was
added to each well and incubated for at least 1 h shaking at room
temperature. Blocking reagent was manually dumped from plates.
Fifty microliters of primary antibody solution {1:5000 anti-NF-
κB [p65 (C-20) rabbit polyclonal from Santa Cruz, catalog no.
sc-372] in 5% NGS in 1×PBS/0.1% Tween} was added to each
well. Plates were incubated overnight with gentle rocking at 4°C.
The primary antibody solution was aspirated. Plates were washed
with 150µl 1×PBS/0.1% Tween for 6 min while shaking at room
temperature, four times. The wash solution was added with the
Janus Workstation and dumped manually. Fifty microliters of
Goat anti-rabbit Alexa Fluor 488 nm secondary antibody (Life
Technologies, 1:1000) and Hoechst 34328 stain (Life Technolo-
gies, 1:1000) in 5% NGS in 1×PBS/0.1% Tween were added to
each well. Plates were shielded from light and incubated at room
temperature for at least 1 h shaking. The secondary antibody solu-
tion was dumped from plates. Plates were washed with 150µl
1×PBS/0.1% Tween twice, then once with 1×PBS for 6 min while
shaking. The wash solution was added with the Janus Workstation
and dumped manually. One hundred fifty microliters of 1×PBS
was added to each well.
Each plate was imaged with an Operetta High-Content Scan-
ner (Perkin Elmer) and the number of cells with nuclear NF-κB in
each well was quantified with Harmony software (Perkin Elmer).
Individual cells were identified based on Hoechst staining of DNA.
The cytoplasm of each cell was then identified based on the detec-
tion of NF-κB staining surrounding individual nuclei. Cells on the
edges of each image were excluded from subsequent analysis, so
that only completely visible cells were quantified. The intensity of
the NF-κB signal in the nucleus was calculated by the Harmony
software. Nuclear NF-κB was defined as an NF-κB signal that over-
lapped with the Hoechst stain. Based on the negative and positive
controls in each plate, an intensity threshold was defined for each
plate that identified cells with predominant nuclear NF-κB sig-
nals, i.e., where the bulk of the NF-κB signal overlapped with the
Hoechst signal. The intensity threshold was set to>400–800 mean
pixel intensity depending on the plate. The remaining wells of the
plate were then automatically visualized and quantified. Between
two and eight images were captured per well, depending on the
cell density in the respective plates, with total cell count per well
averaging 766.4. For the validation screens, 8–12 images per well
were captured. The HeLa cell validation screen counted an aver-
age of 2056.3 cells per well, while the A549 cell validation screen
counted an average of 2023.5 cells per well. A formula was set up
in the analysis sequence to find the percentage of cells with nuclear
NF-κB in each well: (number of cells with a strong nuclear NF-κB
signal/total number of cells)× 100.
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RNAi SCREEN
The siRNA screen was performed with Dharmacon siGENOME
SMARTpool siRNA pools that target human ubiquitin conjuga-
tion enzymes and human deubiquitylating enzymes. Transfec-
tions were performed in duplicate for each plate at each time
point assayed. All liquid handling steps were performed with
a PerkinElmer Janus Automated Workstation. For transfections,
85µl of DMEM culture medium (+FBS/−antibiotics) containing
HeLa cells (1500 cells per well) or 85µl of DMEM/F12 cul-
ture medium (+FBS/−antibiotics) containing A549 cells (2000
cells per well) were added to each well. Plates were incubated
overnight at 37°C. The next day, siRNA was diluted to 200 nM
(10µl per well) in nuclease-free water in a mixing plate. Five
microliters of Polyplus Interferin-HTS diluted in nuclease-free
water (0.1µl interferin-HTS+ 4.9µl nuclease-free water in each
well) was added to each well containing siRNA and was mixed
by slowly pipetting up and down. The transfection reagent and
siRNA were incubated for 20–30 min at room temperature. Fif-
teen microliters of the transfection reagent–siRNA complex were
mixed again by pipetting, and then added to the plates containing
the cells (final siRNA concentration= 20 nM). Plates were mixed
by gently tapping the sides of the plate 20–30 times and then
incubated for 3 days at 37°C.
VALIDATION SCREENS
The siRNA validation screens were performed using a custom plate
of Dharmacon siGENOME individual siRNAs corresponding to
the major hits from the original screen (Figure 6A). Each gene
was tested with four distinct siRNA duplexes to test potential off-
target effects from the pooled siRNA. The plating of cells and the
RNAi transfections were executed as above.
z -SCORE ANALYSIS
We used z-score analysis to normalize the percentage of cells with
nuclear NF-κB values for the entire screen. The z-score assumes
normal distribution and represents the standard deviation of well
measurement value from the plate median for each dsRNA treat-
ment. z-Scores were calculated by subtracting the sample value
by the plate median value and dividing by the plate standard
deviation. z-Scores above 1.96 or below −1.96 represent the 95%
confidence interval.
REVERSE TRANSFECTION OF siRNA
For the orthogonal assays described in Figure 8 through
Figure 11, cells were reverse transfected with individual siRNA
duplexes (Dharmacon siGENOME individuals: CUL1 D-004086-
03; TNFAIP3 D-009919-02; USP7 D-006097-01, -02, -03, -
04; USP12 D-027148-01, -02, -03, -04; USP49 D-005945-06,
-05, -04, -02; USP54 D-016853-17, -04, -02, -01; FBXO36 D-
018460-04, -03, -02, -01; KMT2D D-004828-01, -02, -03, -
05) and control siRNA (Dharmacon siGENOME non-targeting
siRNA pool no. 1, D-001206-13-05). HeLa: in a 6-, 12-, or 96-
well plate, the diluted transfection reagent (0.028µl Polyplus
Interferin-HTS and 4.972µl nuclease-free water) was added to
each well (6-well= 100µl; 12-well= 50µl; 96-well= 5µl). Ten
micromolar of siRNA was diluted 1:50 in nuclease-free water
(siRNA concentration= 200 nM) and was added to each well (6-
well= 200µl; 12-well= 100µl; 96-well= 10µl). The transfection
reagent and the siRNA were combined by carefully pipetting up
and down five times, and the transfection mixture was incubated
at room temperature for 20–30 min. HeLa cells in DMEM culture
medium (+FBS/−antibiotics) at 3× 105 cells/ml (western blot
and qRT-PCR) or 3.63× 104 cells/ml (TUNEL) (6-well= 1.7 ml;
12-well= 850µl; 96-well= 85µl) were added to each well and
were mixed with the transfection mixture by rocking the plate
followed by gently tapping the sides of the plate (siRNA final
concentration= 20 nM). Cells were incubated with the siRNA
for 3 days at 37°C. A549: the diluted transfection reagent [6-
well= 2µl DharmaFECT 1 (Dharmacon) and 148µl Opti-MEM
(Gibco); 12-well= 4µl DharmaFECT 1 and 296µl Opti-MEM]
was added to each well. Ten micromolar of siRNA was diluted
1:50 in Opti-MEM and was added to the transfection reagent
by pipetting up and down. The transfection mixture was incu-
bated at room temperature for 30 min. A549 cells in DMEM/F12
(+FBS/−antibiotics) at 3× 105 cells/ml were added to each well
and were mixed as described above.
WESTERN BLOT ANALYSIS
Cells were reverse transfected in a 12-well plate, as described above.
Following the incubation, the culture medium was aspirated from
each well and replaced with 500µl of 10 ng/ml TNF in DMEM
(+FBS/−antibiotics) or a control solution of DMEM only, and
the samples were incubated at 37°C for the appropriate amount of
time. DMEM and TNF solutions were then aspirated. Fifty micro-
liters of fresh lysis buffer (20 mM Tris, pH 7.5; 25 mM glycerol-
3-phosphate; 150 mM NaCl; 1% Triton X-100; 2 mM Na3VO4;
protease inhibitors) was quickly added to each well and samples
were harvested by scraping the well with a plastic cell lifter. Lysates
were added to 40µl 2× sample buffer [62.5 mM Tris, pH 6.8;
10% (v/v) glycerol; 2% (w/v) SDS; 50 mM β-mercaptoethanol;
0.00125% (w/v) bromophenol blue] and boiled for 5 min. Pro-
teins were separated by SDS-PAGE electrophoresis and transferred
to a nitrocellulose membrane by semi-dry transfer. Membranes
were blocked in blocking buffer (LI-COR Biosciences) for 1 h
at room temperature and probed with antibodies against total
I-κB [1:1000, cell signaling, no. 4812S, IkappaBalpha (44D4) Rab-
bit mAb], phosphorylated I-κB [1:1000, cell signaling, no. 9246S,
P-IkappaBalpha (S32/36) (5A5) Mouse mAb], Tubulin (1:1000,
DSHB, E7 mouse supernatant), phosphorylated JNK [1:1000,
Promega, Anti-Active JNK (pTPpY) pAb Rabbit, no. 9255S], USP7
(1:200, cell signaling, HAUSP Rabbit Ab, no. 3277S), or beta-
catenin (1:500, cell signaling, beta-catenin Rabbit Ab, no. 9562S)
where indicated in blocking buffer with 0.1% (v/v) Tween-20
overnight at 4°C. The membranes were washed four times in PBS
with 0.1% (v/v) Tween-20 for 5 min at room temperature and
incubated with a 1:10,000 dilution of the Alexa Fluor 680 or 750
conjugated secondary antibodies (molecular probes).
QUANTITATIVE REAL-TIME PCR ANALYSIS
Cells were reverse transfected in a six-well plate as described above.
Following the incubation, total RNA was extracted from approxi-
mately 4× 106 cells using TRIzol reagent (Life Technologies). The
culture media was aspirated from each well and 200µl of TRIzol
was added. Lysed cells were removed by scraping the wells with a
cell lifter and RNA was extracted according to the manufacturer’s
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protocol. The RNA samples were purified of DNA by treatment
with DNase I (Invitrogen). cDNA was generated from 5µg of
RNA using qScript cDNA SuperMix (Quanta Biosciences) accord-
ing to the manufacturer’s protocol. A 1:16 dilution of the cDNA
was employed for analysis. Transcript amplification was moni-
tored with the Eppendorf realplex software, using KAPA SYBR
FAST Universal 2× qPCR master mix (KAPA Biosystems) and the
following primers: USP7 forward 5′-AAA TGG TGT AAA TTT
GAT GAC GAC G-3′, reverse 5′-CAA AAC TGG TCC TCT GCG
ACT ATC-3′; USP12 forward 5′-AAA TAA TAA CAG CAC ACC
AGA CC-3′, reverse 5′-TTT GCT GCT TAT AGT TTC ACA AG-3′;
USP49 forward 5′-ACC AGT GTA ACA GCA AAC GAC-3′, reverse
5′-TCA TTA ACT GCT TTC TAG CTT CAC-3′; USP54 forward
5′-ACC ACA GTG AAG GAG AAA CAC-3′, reverse 5′-CCA GGG
ATG GTC TGT TAT G-3′; FBXO36 forward 5′-CAC ATC TTC AAG
GTC AAA CTG-3′, reverse 5′-GAT AGT CAG GAG CAA ATC
GTC-3′; KMT2D forward 5′-GCC AAG CCT GCA GGA AAC-
3′, reverse 5′-CAC GTC TCA CAA ACC AAC ATC-3′. Transcript
expression levels for each experimental sample were normalized
to actin expression levels (actin forward 5′-AAG ACC TGT ACG
CCA ACA C-3′, reverse 5′-TCC ACA CGG AGT ACT TGC-3′)
for that sample and to the non-targeting control sample using the
∆∆CT method.
TUNEL ASSAY
Cells were reverse transfected as described above. Following the
incubation, the culture medium was aspirated from each well
and replaced with 50µl of DMEM culture medium containing
10 ng/ml TNF and 10µg/ml cycloheximide (Sigma) for 8 h at
37°C. The medium was aspirated and 100µl 3.7% formaldehyde
in PBS was added to each well. The plate was rocked manu-
ally 10–15 times and incubated at room temperature for at least
15 min without shaking. Formaldehyde was removed from the
plate and the plate was washed with 100µl 1×PBS for 6 min while
shaking at room temperature, two times. Cells were permeabi-
lized by adding fresh 0.1% sodium citrate/0.1% Triton X-100
in 1×PBS and incubating on ice for 2 min. The sodium cit-
rate solution was removed from the plate. The plate was washed
with 100µl of 1×PBS for 6 min while shaking at room temper-
ature, two times. The in situ cell death detection kit, TMR red
(Roche), was employed to label apoptotic cells. Twenty micro-
liters of fresh TUNEL reaction mixture (2µl enzyme solution 1
and 18µl label solution 2) was added to each well and samples
were incubated at 37°C for 1 h. TUNEL reaction mixture was
removed from the plate and the cells were washed with 100µl
1×PBS for 6 min while shaking at room temperature, three times.
DNA was labeled by incubating cells with 50µl Hoechst 34328
stain (Life Technologies, 1:1000) in 1×PBS for at least 10 min
and the plate was washed one more time in 100µl 1×PBS. Cells
were imaged using the Operetta High-Content Scanner (Perkin
Elmer) and the number of TUNEL-positive cells in each well was
quantified with Harmony software. The nuclei of individual cells
were identified based on Hoechst staining of DNA. Cells on the
edges of each image were excluded from subsequent analysis, so
that only completely visible cells were quantified. The intensity of
the TUNEL signal in the nucleus was calculated by the Harmony
software. Nuclear TUNEL was defined as a TUNEL signal that
overlapped with the Hoechst stain. Based on the negative and pos-
itive controls in each plate, an intensity threshold was defined for
each plate that identified cells with predominant TUNEL signals.
The intensity threshold was set to 450 mean pixel intensity. The
remaining wells of the plate were then automatically visualized
and quantified.
RESULTS
A HIGH-CONTENT ASSAY FOR THE NUCLEAR LOCALIZATION OF NF-κB
We developed a rapid and sensitive high-content assay to identify
ubiquitin modifiers that regulate intracellular signals in response
to TNF (Figure 1A). In this assay, we incubated HeLa cells in
96-well plates with pools of siRNA duplexes that target ubiquitin
pathway elements. Eighty wells contained siRNA pools that tar-
geted ubiquitin modifying enzymes, 10 wells did not contain any
siRNA duplexes, 3 wells contained control non-silencing siRNAs,
and 3 wells contained duplexes that targeted the ubiquitin-editing
enzyme A20. Loss of A20 results in prolonged nuclear translo-
cation of NF-κB in HeLa cells treated with TNF and serves as a
reliable positive control for gene products that alter the activation
of NF-κB.
We initially visualized and quantified the nuclear transloca-
tion of NF-κB at different times of TNF incubation (Figure 1B).
NF-κB was predominantly cytosolic in cells that were not treated
with TNF, translocated to the nucleus by 30 min TNF treat-
ment, and gradually relocated to the cytosol with increasing
periods of TNF exposure. From these results, we selected two
time points to assay for modifiers of NF-κB localization. We
tested the entire siRNA collection for duplexes that diminish the
nuclear translocation of NF-κB at 30 min TNF incubation. We rea-
soned that such duplexes identify gene products that contribute
to the nuclear localization of NF-κB. We also looked for siRNA
duplexes that enhance the nuclear accumulation of NF-κB at
120 min TNF exposure. Such duplexes uncover candidate gene
products that revert the subcellular localization of NF-κB at later
times.
SCREEN FOR UBIQUITIN MODIFIERS THAT ALTER NUCLEAR
LOCALIZATION OF NF-κB
In total, we tested a collection of 700 siRNA pools for effects
on the nuclear translocation of NF-κB in response to TNF. We
used standard score (z-score) analysis to determine the magni-
tude each siRNA pool alters the subcellular localization of NF-κB.
The z-score is a measure of the extent to which an experimen-
tal group deviates from the median group within the same plate
and is ideal for plate-to-plate comparisons. z-Scores above 1.96 or
below−1.96 represent the fifth percentile groups of modifiers and
are typically considered statistically significant. The results for each
siRNA pool are presented in Tables S1–S4 in Supplementary Mate-
rial. As expected, the bulk of experimental siRNAs had low z-scores
at 30 and 120 min TNF exposure and do not appear to have a sig-
nificant impact on the transduction of signals from TNF to NF-κB
(Figures 2A,D). Likewise, control non-silencing siRNA duplexes
did not modify the response of NF-κB to TNF at either time point
(Figures 2C,F). The A20 siRNA duplexes did not prevent a nuclear
accumulation of NF-κB at 30 min TNF incubation (Figure 2B),
but frequently resulted in elevated z-scores suggest that prolonged
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FIGURE 1 | (A) Overview of key steps in the high-content assay. Step 2
shows the organization of siRNA pools within each plate.
(B) Representative images of cells treated with TNF for 0, 30, and 120 min,
and stained for NF-κB (green) and nuclear DNA (blue). Representative cells
with cytosolic NF-κB are shown with white arrowheads and cells with
nuclear NF-κB are shown with orange arrowheads. The bar chart shows the
percentage of cells with nuclear NF-κB at the indicated times of TNF
exposure. Results are shown as the average of three independent
measurements and error bars indicate standard deviations. Statistical
analysis was performed with a one-way ANOVA analysis, and one and two
asterisks indicate p values below 0.05 and 0.01, respectively.
nuclear accumulation of NF-κB at 120 min TNF exposure and
are consistent with the physiological function of A20 (Figure 2E).
Finally, comparison of the replicate assays indicated reproducible
phenotypes for the majority of the siRNA duplexes tested at both
time points (Figures 2G,H). In short, preliminary evaluation of
the screen data suggests that the siRNA duplexes reproducibly
generated predictable phenotypes that include a small number of
significant modifiers of TNF-mediated nuclear accumulation of
NF-κB.
UBIQUITIN MODIFIERS OF SIGNALS FROM TNF TO NF-κB
The primary screen identified 12 putative modifiers of NF-κB
localization at 30 min TNF treatment (Table 1) and an additional
9 putative modifiers at 120 min TNF exposure (Table 2).
We consider it noteworthy that several modifiers identified
in our primary screen (e.g., CUL1, FBXW11, RNF31/HOIP, and
TNFA1P3/A20) are known TNF pathway members. Furthermore,
the phenotypes ascribed to the individual gene products overlap
with the known molecular function of the target gene. Our ability
to identify several known TNF pathway elements in an unbiased
reverse genetics approach suggests an acceptable false-negative rate
in the screen. Indeed, examination of the z-scores attributed to
known TNF pathway members indicated that we consistently rated
TNF pathway elements as substantial modifiers of NF-κB nuclear
translocation (Figure 3). Of the 10 TNF pathway members tested,
5 (HOIP, A20, UBE2V1, CUL1, and FBXW11) were significant
modifiers, and an additional 2 (c-IAP1 and HOIL-1) generated
moderate phenotypes that matched their established biochemi-
cal functions. Two modifiers at 30 min (KRTAP5-9 and KMT2D)
do not have obvious relationships to the ubiquitin pathway. We
noticed an overrepresentation of deubiquitylation enzymes and
underrepresentation of E3 ligases in the preliminary list of puta-
tive modifiers (Figure 4). The bias of hits toward deubiquitylation
enzymes and away from E3 ligases may reflect differing functional
redundancies within the respective groups.
PHENOTYPIC CLASSES OF UBIQUITIN PATHWAY MODIFIERS
We visually inspected the remaining putative modifiers to con-
firm the reported phenotypes. The results shown in Figure 5 are
representative images of samples treated with a pool of siRNA
duplexes and TNF for 30 min. As a reference, we included images
of cells treated with DUB1A siRNA. DUB1A does not appear to
play a role in the nuclear translocation of NF-κB and the bulk of
HeLa cells have a visible nuclear accumulation of NF-κB. In con-
trast, cells treated with CUL1 siRNA have a pronounced absence
of nuclear NF-κB at 30 min TNF treatment, consistent with the
established requirement for CUL1 in the K48 ubiquitylation of I-
κB. The majority of putative modifiers had visual phenotypes that
agreed with the reported z-scores. However, we also detected two
novel phenotypes within the list of putative modifiers. One siRNA
pool (FBXO5) had greatly enlarged nuclei suggest that defects in
cell division, and matches a known requirement for FBXO5 in
progression through mitosis. An additional three pools resulted
in widespread cell death. For example, treatment of HeLa cells
with an siRNA pool that targets SIAH2 led to extensive loss of cells
within 3 days. We excluded pools that led to pronounced cell death
or nuclear enlargement from subsequent analysis.
VALIDATION OF MODIFIERS FROM THE PRIMARY SCREEN
The phenotypes described in the primary screen were observed
with pools of four siRNA duplexes that target non-overlapping
sections of a mutual target. This approach permits an increased
throughput in primary screens, but fails to adequately address
concerns about potential off-target effects that result from the
unintended depletion of non-targeted transcripts. To determine
the extent to which off-target effects generated “hit” phenotypes
in our primary screen, we performed a validation screen where
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FIGURE 2 | Results of a high-content screen for ubiquitin modifiers
of NF-κB. (A–E) The distribution of z -scores are shown for all samples
(A,D); samples treated with control, non-silencing siRNAs (NS, C, and
F); or samples treated with controls A20 siRNA (B,E). (A–C) Show the
z -score distributions for all samples at 30 min TNF and (D–F) show the
z -score distribution for all samples at 120 min TNF. (G–H) Scatterplots
show the replicate z -scores for the respective siRNAs at 30 min TNF
(G) and 120 min TNF (H). (H) Red dots show the z -scores for control
A20 siRNAs and green dots show the z -scores for control non-silencing
siRNAs.
Table 1 | Ubiquitin pathway modifiers ofTNF signaling at 30 min.
Gene ID Name Class Phenotype Lethal Nuclear Potential immune function
(NCBI gene report)
NM_001014283 DCUN1D2 Neddylation Reduced nuclear translocation N N Neddylation of CUL1 (25)
NM_003592 CUL1 SCF E3 component Reduced nuclear translocation N N Ubiquitylation of I-κB (26)
NM_024907 FBXO17 SCF E3 component Reduced nuclear translocation Y Y None
NM_033645 FBXW11 SCF E3 component Reduced nuclear translocation N N Ubiquitylation of I-κB (27)
NM_003482 KMT2D Lysine methyl transferase Reduced nuclear translocation N N No clear connection to ubiquitin pathway
NM_001024941 TRIM17 RING motif E3 ligase Reduced nuclear translocation N N None
NM_017999 RNF31 RING motif E3 ligase Reduced nuclear translocation N N AKA HOIP (28)
NM_005553 KRTAP5-9 Keratin protein Reduced nuclear translocation N N No clear connection to ubiquitin pathway
NM_005805 PSMD14 Deubiquitylation Reduced nuclear translocation Y N Proteasomal component
NM_182488 USP12 Deubiquitylation Reduced nuclear translocation N N Drosophila IMD response (29)
NM_031907 USP26 Deubiquitylation Reduced nuclear translocation N N None
NM_020718 USP31 Deubiquitylation Reduced nuclear translocation N N NF-κB activation (30)
we tested each individual siRNA alone for modification of NF-
κB responses to TNF in HeLa cells and adenocarcinoma A549
cells. The organization of siRNA duplexes within the validation
plate is shown in Figure 6A. In this assay, we defined an siRNA
duplex as a modifier if it resulted in a nuclear accumulation of NF-
κB that was greater than two standard deviations away from the
median nuclear accumulation observed for cells treated with the
control non-silencing siRNA (Figure 6B; Table S5 in Supplemen-
tary Material). For several targets, two or more individual duplexes
generated phenotypes that matched our observations in the pri-
mary screen (e.g., FBXW11, HOIP, USP12, and A20; Figure 6B).
In contrast, we found a number of cases where multiple individ-
ual duplexes failed to replicate the results of the primary screen
(e.g., DCUN1D, USP54, TRIM17, and USP26). Our inability to
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Table 2 | Ubiquitin pathway modifiers ofTNF signaling at 120 min.
Gene ID Gene name Class Phenotype Lethal Nuclear Potential immune function
(NCBI gene report)
NM_001032288 UBE2V1 E2 Prolonged nuclear translocation N N NF-κB pathway regulation (31)
NM_012180 FBXO8 SCF E3 component Prolonged nuclear translocation N N None
NM_183413 FBXO44 SCF E3 component Prolonged nuclear translocation Y N None
NM_174899 FBXO36 SCF E3 component Prolonged nuclear translocation N N None
NM_006290 TNFA1P3 Ubiquitin-editing Prolonged nuclear translocation N N AKA A20. Termination of TNF signals (24)
NM_018561 USP49 Deubiquitylation Prolonged nuclear translocation N N None
NM_203494 USP50 Deubiquitylation Prolonged nuclear translocation N N Cell cycle
NM_152586 USP54 Deubiquitylation Prolonged nuclear translocation N N None
NM_003470 USP7 Deubiquitylation Prolonged nuclear translocation N N Activation of NF-κB (32)
FIGURE 3 | Graphical representation of replicate assay z-scores
assigned to known ubiquitin ligase modifiers of theTNF–NF-κB
pathway in the primary siRNA screen.
replicate primary screen data with individual duplexes for several
genes indicates that our initial screen generated several false pos-
itive hits. Statistical analysis of the primary data suggests that a
false discovery rate of 0.501 in our screen.
Comparison between cell types uncovered a marked differ-
ence between A549 cells and HeLa cells. In particular, very few
duplexes resulted in enhanced nuclear accumulation of NF-κB
FIGURE 4 |The bar chart shows the relative percentages of E1, E2, and
E3 ubiquitin ligases, and deubiquitylation enzymes identified as
modifiers of theTNF pathway at 30, 120 minTNF exposure and in total.
The expected column shows the anticipated distribution assuming a normal
representation of the respective functional groups.
in A549 cells treated with TNF for prolonged periods. We inter-
pret these data to suggest that A549 cells have a reduced ability to
terminate TNF signals, as numerous TNF-responsive transcripts
actively interrupt the nuclear accumulation of NF-κB and gene
products such as CUL1, FBXW11, and HOIP are known targets of
the TNF transcriptional machinery. Consistent with this hypothe-
sis, we observed a substantially greater accumulation of NF-κB in
HeLa cells depleted of A20 than in A549 cells.
We preliminarily defined a candidate as a potential hit if a
minimum of two non-overlapping siRNAs yielded a modifier
phenotype that mirrored the results observed in the primary
screen. By these selection criteria, we identified four modifiers at
30 min TNF (CUL1, FBXW11, KMT2D, and USP12) treatment
and an additional five modifiers at 120 min TNF (A20, USP7,
USP49, USP54, and FBXO36) in HeLa cells. We observed identi-
cal 30 min TNF phenotypes for CUL1 and FBXW11 in A549 cells,
a similar, although delayed phenotype for KMT2D, and a simi-
lar, but milder phenotype for USP12. As expected, the inhibitory
phenotypes identified in HeLa cells were less pronounced upon
inactivation of the same gene product in A549 cells. Nonethe-
less, a minimum of two siRNA molecules led to increased levels
of nuclear NF-κB in A549 cells depleted of A20, USP7, USP49,
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FIGURE 5 | Representative images of HeLa cells treated with the
indicated siRNA pools and incubated withTNF for 30 min. Each panel is
shown at the same scale. NF-κB is shown in green in the merged image
and DNA is shown in blue. CUL1 siRNA is a representative inhibitor of
NF-κB nuclear accumulation, FBXO5 siRNA results in enlarged nuclei, and
SIAH2 siRNA leads to extensive cell death.
USP54, or FBXO36 and treated with TNF for 120 min. Of these
modifiers, three have clearly established roles in the regulation of
TNF-dependent nuclear translocation of NF-κB (CUL1, FBXW11,
and A20). In each case, the phenotypes described in the primary
and validation screens overlap with the known molecular function
of the respective gene products. In short, primary and secondary
analysis indicates that the high-content approach detailed in this
project detects a number of bona fide modifiers of the TNF–NF-
κB axis, although orthogonal assays are required to identify false
positives.
We then used qPCR (Figure 7A) and Western blot analy-
sis (Figure 7B) to determine the extent to which the individual
siRNA duplexes affected expression of the target genes. As antic-
ipated, the effects of the individual duplexes varied. In general,
A549 cells appear more sensitive to the effects of RNAi. qPCR
data suggest that RNAi-mediated inactivation of USP49, FBXO36,
and USP12 depleted levels of the corresponding transcripts. In
contrast, most KMT2D and USP54 duplexes had no appreciable
effect on transcript levels. For several gene products (USP7,USP12,
FIGURE 6 | (A) Arrangement of experimental and control siRNA duplexes in
a secondary assay for ubiquitin modifiers that control the nuclear
translocation of NF-κB. (B) Graphical overview of the nuclear accumulation
of NF-κB as a number of standard deviations from control non-silencing
siRNA duplexes in HeLa or A549 cells treated with the respective siRNA
duplexes and TNF for the indicated periods.
and FBXO36), we observed a correlation between the extent of
target knock-down and the severity of the cellular phenotype
(Figure 7C).
INTERACTIONS OF PUTATIVE UBIQUITIN PATHWAY MODIFIERS OF
NF-κBWITH I-κB
Based on the validation data presented in Figures 6 and 7, we per-
formed a series of orthogonal assays to probe the involvement of
USP7, USP12, USP49, and FBXO36 in TNF pathway activity. We
do not consider USP54 and KMT2D suitable candidates for study,
Frontiers in Immunology | Inflammation July 2014 | Volume 5 | Article 322 | 8
Fraser et al. Ubiquitin modifiers of TNF pathway
FIGURE 7 | (A) Expression of the indicated genes in HeLa cells (open
boxes) and A549 cells (gray boxes) treated with the corresponding siRNA
(numbered 1–4). Box plots represent the three independent measurements
and expression levels are reported relative to cells treated with a control
non-silencing siRNA. Statistical evaluations were performed with a one-way
ANOVA analysis comparing each sample mean to the non-silencing mean
individually. One, two, and three asterisks indicate p values below 0.05,
0.01, and 0.001, respectively. (B) Western blot evaluation of lysates from
A549 and HeLa cells treated with a control non-silencing siRNA (NS), or
four independent siRNA duplexes that target USP7. Samples were probed
with anti-USP7 antibodies and counter-probed with a tubulin antibody as a
loading control. (C) Rank score evaluation of phenotypic severity for
individual siRNAs that target USP12, USP7, and FBXO36 (z -score), and
knock-down efficiency (knock-down for the corresponding siRNAs). z -Score
data for USP12 are from the 30 min TNF exposure data presented in
Figure 6, and z -score data from USP7 and FBXO36 are from the 120 min
TNF exposure data presented in Figure 6.
given the lack of target knock-down by the corresponding siRNA
duplexes. For all orthogonal assays (Figures 8–11), we used single
siRNA duplexes to target each gene. Specifically, we used duplex
FIGURE 8 | Western blot evaluation of total I-κB and phosphorylated
I-κB (P-I-κB) in cells treated with the indicated siRNAs and incubated
withTNF for the indicated times. In the merged images, I-κB is shown in
green and P-I-κB is shown in red. Tubulin is shown as a loading control and
numbers on the side indicate molecular weights in kilodaltons.
no. 2 to target USP7; duplex no. 2 to target USP12; duplex no. 3
to target USP49; and duplex no. 3 to target FBXO36.
Signals from TNF lead to the phosphorylation, ubiquitylation,
and destruction of I-κB with a concomitant nuclear translocation
of NF-κB. A subset of NF-κB-responsive transcripts, such as I-κB
and A20, terminate the signal through the sequestration of NF-
κB and the editing of ubiquitylated TNF pathway components,
respectively. The causal relationship between phosphorylation-
dependent ubiquitylation of I-κB and nuclear translocation of NF-
κB led us to explore the impact of hits from the secondary screen
on I-κB. For these assays, we treated cells with siRNA duplexes
that target putative modifiers of NF-κB nuclear accumulation at
30 min TNF (CUL1 and USP12) and at 120 min TNF (A20, USP7,
USP49, and FBXO36). For the former group of siRNAs, we exam-
ined the extent of I-κB phosphorylation and destruction at early
times after TNF exposure. For the latter group of siRNAs, we exam-
ined the early turnover of I-κB 10 min after TNF exposure and the
subsequent re-accumulation of I-κB 120 min after TNF exposure.
As expected, we detected a rapid phosphorylation of I-κB and a
decrease in total I-κB levels by 10 min, and a re-accumulation
of I-κB by 120 min in cells treated with TNF and a control
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FIGURE 9 | Western blot evaluation of total phosphorylated JNK
(P-JNK) in cells treated with the indicated siRNAs and incubated with
TNF for the indicated times. In the merged images, P-JNK is shown in
green and tubulin is shown in red. Molecular weights are shown in
kilodaltons.
non-silencing siRNA (Figure 8A). Loss of USP49 or FBXO36
did not have noticeable effects on the dynamics of I-κB stability
(Figure 8A). However, we noticed a persistent late stage phos-
phorylation of I-κB in cells treated with FBXO36 siRNA that was
absent from cells treated with a control siRNA. As expected for a
gene product that terminates TNF signals to NF-κB, loss of A20
prevents re-accumulation of I-κB 120 min after incubation with
TNF (Figure 8B). Loss of USP7 diminished I-κB at all time points
tested (Figure 8B), indicating a relationship between USP7 activity
and I-κB protein levels. Depletion of CUL1 or USP12 resulted in a
pronounced accumulation of phosphorylated I-κB at 10 min TNF
incubation (Figure 8C). These observations suggest that CUL1
and USP12 are involved in the proteasomal turnover of phospho-
rylated I-κB. As USP49 duplexes had minimal effects on USP49
expression, or I-κB protein turnover, we excluded USP49 from fur-
ther analysis. We selected USP7, USP12, and FBXO36 as promising
leads for the identification of novel ubiquitin pathway elements
that determine the outcomes of TNF signals.
INTERACTIONS OF PUTATIVE UBIQUITIN LIGASE MODIFIERS OF NF-κB
WITH JNK
As the TAB2–TAK1 module drives the transient phosphorylation
of JNK by MAPKK4 and MAPKK7 in response to TNF, we exam-
ined the relationship between ubiquitin pathway components and
the transduction of signals from TNF to JNK. In cells treated
with a non-silencing siRNA, exposure to TNF resulted in robust
JNK phosphorylation by 10 min with a rapid decline in phospho-
JNK levels over time. The phenotype of cells treated with USP12
or CUL1 siRNA deviated mildly from cells treated with control
siRNA; we detected a minor increase in the early TNF-mediated
phosphorylation of JNK and a faster decline in phospho-JNK levels
FIGURE 10 | (A) TUNEL and DNA stain of HeLa cells (upper row), or HeLa
cells treated with TNF and cycloheximide (CHX) for 8 h (lower row).
(B) Relative levels of apoptosis in HeLa cells treated with the indicated
siRNA duplexes and TNF and cycloheximide for the indicated periods. For
each time point, the level of apoptosis in cells treated with non-silencing
(NS) siRNA were assigned a value of 1 and other treatments are reported
relative to the control. (B) Results are the mean of three separate
experiments and error bars indicate the standard deviation. Statistical
analysis was performed with a one-way ANOVA analysis, and one and three
asterisks indicate p values below 0.05 and 0.001, respectively.
FIGURE 11 | Western blot evaluation of beta-catenin (β-catenin) in cells
treated with the indicated siRNAs. Tubulin is shown as a loading control.
Molecular weights are shown in kilodaltons.
(Figure 9A). In cells treated with FBXO36 siRNA, we detected a
moderate, but reproducible prolonged phosphorylation of JNK,
while loss of USP7 results in a decreased phosphorylation of JNK
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(Figure 9B). Combined, our data elaborate the phenotypic con-
tributions of novel ubiquitin pathway members to the TNF signal
transduction pathway. Loss of USP12 results in accumulation of
phosphorylated I-κB, diminished nuclear accumulation of NF-
κB, and modified activation of JNK. In contrast, loss of USP7
results in decreased expression of I-κB, decreased activation of
JNK, and prolonged nuclear accumulation of NF-κB. Depletion of
FBXO36 appears to result in enhanced signal transduction through
the TNF pathway kinase relay, with prolonged phosphorylation of
JNK and I-κB.
INTERACTIONS OF PUTATIVE UBIQUITIN LIGASE MODIFIERS OF NF-κB
WITH APOPTOSIS
In the absence of signal transduction from TNF to NF-κB, engage-
ment of the TNFR typically results in the activation of programed
cell death. We developed a high-content assay to quantify apop-
totic cell death in HeLa cells. For this assay, we incubated HeLa
cells with TNF and prevented the expression of NF-κB-responsive
anti-apoptotic factors through the addition of the translation
inhibitor cycloheximide. As a consequence, signals from the TNFR
induce mitochondrial permeabilization and the induction of cell
death. We used a TUNEL stain to visualize the fragmentation of
nuclear DNA that accompanies apoptotic death. Despite vari-
ability in the extent of cell death in individual replicates, we
consistently detected that addition of TNF and cycloheximide to
HeLa cells resulted in a gradual increase in the levels of apoptosis
(Figures 10A,B). As expected, loss of the pro-apoptotic effector
caspase-8 prevented the induction of cell death and loss of the
TNF pro-survival pathway element TAB2 enhanced cell death
(Figure 10B). Thus, the assay presents a useful forum to inter-
rogate the contribution of gene products to apoptosis. Depletion
of USP7 and USP12 did not substantially modify the induction
of cell death by a TNF–cycloheximide regime. In contrast, loss
of A20 and FBXO36 enhanced the induction of cell death by
TNF and cycloheximide, particularly at early time points. These
observations overlap with an established role for A20 in the pre-
vention of TNF-dependent death and hint at a similar function
for FBXO36.
AN ORTHOLOGOUS ASSAY FOR PUTATIVE UBIQUITIN PATHWAY
MODIFIERS OF THE TNF RESPONSE
The primary and secondary data presented in this report support
roles for USP7, USP12, and FBXO36 in the control of the TNF
pathway. In our original assay, we explored the regulation of NF-κB
nuclear translocation, a process that requires I-κB ubiquitylation
by the SCF–bTrCP E3 ligase. To explore relationships between
candidate ubiquitin pathway members and the SCF–bTrCP com-
plex, we examined beta-catenin levels in cells depleted of USP7,
USP12, and FBXO36, respectively (Figure 11). Beta-catenin is
a target for ubiquitylation by SCF–bTrCP, and we hypothesized
that modifiers of I-κB ubiquitylation will alter steady state lev-
els of beta-catenin. Consistent with this hypothesis, loss of CUL1
resulted in increased levels of beta-catenin. Likewise, depletion of
USP12, USP7, or FBXO36 increased total cellular levels of beta-
catenin. These results support a general role for USP7, USP12, and
FBXO36 as putative modifiers of the SCF–bTrCP E3 ligase.
DISCUSSION
Ubiquitin adds a sophisticated and frequently underappreciated
degree of complexity to cellular events. Ubiquitin conjugates deter-
mine the half-life, localization, and function of substrate proteins
and regulate the assembly of macromolecular complexes into
functional groups. Remarkably, we know very little about the
coordination of ubiquitin and TNF pathway responses during
inflammation. For example, the ubiquitylated complex I element
that recruits TAB2–TAK1 is unknown, and the deubiquitylation
enzymes that remove linear and K63-linked ubiquitin chains from
complex I components require characterization. To address this
issue, we conducted a ubiquitin pathway siRNA screen for enzymes
that regulate TNF-mediated nuclear translocation of NF-κB. We
confirmed established TNF signaling modifiers and identified
several novel candidate components. We believe that the candi-
date proteins represent potentially valuable targets for therapeutic
regulation of TNF-mediated inflammation.
Off-target effects that result from the unintended inactivation
of a non-targeted transcript are a frequent source of concern in
RNAi screens (33). In this report, we describe an unbiased RNAi
platform and a series of orthogonal cell culture based studies
that position a cohort of novel gene products within the TNF
pathway. We believe that this cohort is a valuable set of targets
for evaluation in animal models. However, additional studies are
required to substantiate roles for the individual gene products in
the TNF to NF-κB axis. While there is a body of literature to
support a role for USP7 in the TNF pathway, the involvement of
USP12 and FBXO36 required additional validation experiments.
It is common practice for investigators to validate a phenotype
with additional dsRNAs, molecular, biochemical, and cell biologi-
cal studies, and where possible an examination of an animal model
where the target gene is inactivated through conventional mutage-
nesis techniques. We believe secondary assays that probe the effects
of USP12 and FBXO36 on transcriptional responses to TNF are
good candidates for follow-up experiments.
We consider false negatives an equally important and often
neglected source of concern in RNAi screens. False negatives arise
when a relevant gene product is not sufficiently depleted in a par-
ticular screen or when the screen itself is not robust enough to
uncover meaningful hits. A recent bioinformatic study indicated
that false negatives are a common source of error in RNAi screens
(34). We note that false negatives are clearly an issue in our screen,
as our secondary selection criteria excluded the known LUBAC
component HOIP from a more detailed analysis. Investigators can
mitigate the impact of false negatives to some extent by optimizing
the sensitivity of their screen and by testing several dsRNA mole-
cules for each target, but we consider it likely that current screening
technologies have an appreciable frequency of false negatives.
With these considerations in mind, we recommend investiga-
tors take a parsimonious approach in the evaluation of primary
data from large-scale RNAi screens, including the one presented
here. The entire data set of our primary screen is available in
Tables S1–S4 in Supplementary Material. Apparent phenotypes
should not be considered truly biologically relevant without in-
depth follow-up studies, and absence of a phenotype should
not be considered absence of a function. We are satisfied that
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USP7, USP12, and FBXO36 are reasonable candidates for con-
sideration as TNF modifiers, as we detected reproducible phe-
notypes in duplicate assays with siRNA pools and individual
duplexes, and generated clear phenotypes in secondary assays that
interrogated specific aspects of TNF signaling. On a cautionary
note, our studies were limited to direct examination of NF-κB
localization and did not examine downstream transcriptional
events.
In vitro studies indicate interactions between USP7 and TNF
pathway members TRAF2 and NEDD4 (35). The USP7 pheno-
type described in this report is quite complex, as depletion of
USP7 led to a loss of I-κB protein and a stabilization of beta-
catenin. The constitutive loss of I-κB protein observed upon
depletion of USP7 may reflect a non-proteasomal requirement
for USP7 in transcriptional processes. Recent publications identi-
fied functional relationships between USP7 and the regulation of
apoptosis or NF-κB transcriptional activity in the TNF pathway
(32, 36). These parallel observations support our positioning of
USP7 within the TNF–NF-κB axis. There are no available data on
the role of USP12 in the control of TNF signaling. However, a pre-
vious report from our group identified the Drosophila ortholog
of USP12 as a modifier of the immune deficiency (IMD) path-
way (29). We consider these findings striking, as the IMD and
TNF pathways share an evolutionary conserved core of molecules
that regulate JNK, NF-κB, and caspase responses. To date, FBXO36
has not been described in the literature. However, F box proteins
interact with CUL1 and our data consistently suggested that loss
of FBXO36 results in heightened signal transduction through the
TNF pathway. The simplest explanation for this phenotype is that
disruption of interactions between CUL1 and FBXO36 alter the
activity of SCF–bTrCP.
Biochemical and mutational studies are required to fully estab-
lish the roles of FBXO36, USP7, and USP12 in the TNF pathway.
However, a preliminary organization of the phenotypes identified
for the respective gene products in various secondary assays hint
at functional relationships. For example, USP12 and CUL1 RNAi
phenotypes are strikingly similar in a number of secondary assays,
suggesting similar requirements for both gene products in the
activation of the SCF–bTrCP complex. FBXO36 has a unique phe-
notype that deviates considerably from A20 and CUL1, indicating
a distinct relationship between FBXO36 and the TNF pathway. The
non-overlapping nature of the FBXO36 and USP12 phenotypes
are fortuitous, as they represent unique pharmacological targets
for the manipulation of TNF pathway activity and intensity.
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